YUNGJIN PHARM. CO. LTD

As of June 30, 2026, YUNGJIN PHARM. CO. LTD carries a market capitalization of 217.46B, placing it among publicly traded companies globally. Its enterprise value stands at 291.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, YUNGJIN PHARM. CO. LTD has 182.89M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.86, and the price-to-book ratio stands at 2.52.

As of June 30, 2026, YUNGJIN PHARM. CO. LTD trades at an EV/EBITDA multiple of 61.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 291.12B versus a market cap of 217.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, YUNGJIN PHARM. CO. LTD maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 89.65, indicating elevated leverage, while an interest coverage ratio of 1.20 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, YUNGJIN PHARM. CO. LTD posted a negative return on equity (ROE) of -7.06, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.67, reflecting losses generated across the asset base. The company generates approximately 403.84M in revenue per employee across its workforce of 626.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.72 indicates how many times YUNGJIN PHARM. CO. LTD sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, YUNGJIN PHARM. CO. LTD recorded an income tax benefit of -1.59B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -7.84B and -6.26B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, YUNGJIN PHARM. CO. LTD's stock has declined approximately 52.25% over the past 52 weeks. The 50-day moving average sits at 1,096.56, while the 200-day moving average is 1,483.26.

Over the twelve months ended June 30, 2026, YUNGJIN PHARM. CO. LTD generated 253.00B in revenue and converted that into -6.26B in net income, yielding earnings per share of -34.21. EBITDA reached 4.74B, while operating income came in at -2.93B.

As of June 30, 2026, YUNGJIN PHARM. CO. LTD holds 3.59B in cash and equivalents against 77.24B in total debt, resulting in a net debt position of 72.54B. Total book value stands at 86.16B, with working capital of 36.03B providing operational flexibility.

YUNGJIN PHARM. CO. LTD produced -910.87M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.91B in capital expenditures, free cash flow totaled -7.82B - equivalent to -42.74 per share.

Over the twelve months ended June 30, 2026, YUNGJIN PHARM. CO. LTD posted a gross margin of 29.54, reflecting its pricing power and cost economics. The operating margin of -1.16 and net profit margin of -2.47 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to YUNGJIN PHARM. CO. LTD shareholders.

YUNGJIN PHARM. CO. LTD's most recent stock split took place on June 18, 2010 with a 324:365 split ratio.

As of June 30, 2026, YUNGJIN PHARM. CO. LTD has an Altman Z-Score of 2.05, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.